Therakind enters exclusive distribution partnership with Accord Healthcare
Geographic expansion as Jylamvo is launched in an additional three European countries
23 November 2019 - Therakind Limited, a specialty pharmaceutical company focused on developing niche medicines for difficult-to-treat patient groups, has entered into an exclusive distribution agreement with Accord Healthcare (“Accord”) for Therakind’s lead product, Jylamvo. The partnership also announces today the successful launch of Jylamvo in Poland and Romania.
Under this agreement, Accord secures exclusive rights to market, commercialise and sell Jylamvo in [Poland, Romania, and Czech Republic]. Jylamvo is already on sale in UK, Middle East, Greece and Portugal,
Jylamvo is a novel methotrexate 2mg/ml Oral Solution which is licensed for use in adults and children over three years old for the treatment of rheumatological disorders (adult and juvenile) and adult psoriasis and psoriatic arthritis, and for the maintenance treatment of acute lymphoblastic leukaemia (ALL). Jylamvo has a marketing authorization which allows it to be sold throughout the European Economic Area and is the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).
Jylamvo as an oral liquid is easier for patients with swallowing difficulties to take than tablets and its use eliminates dosing inaccuracies and unnecessary exposure to the cytotoxic methotrexate powder which may occur if tablets are crushed. As a licensed oral liquid, Jylamvo has proven stability and no inappropriate excipients which may be the case with unlicensed oral liquids. Jylamvo also has a palatable orange taste which masks methotrexate’s bitter taste. It also addresses compliance issues which may occur with methotrexate injections due to patients’ fear of needles and intolerance of injection site pain and reaction.
Dr Susan Conroy, CEO of Therakind, said:
“Therakind is committed to providing age-specific medicines designed to improve the lives of our patients. Jylamvo, our flagship product, is an easy to take, pleasant tasting liquid medicine for children and adults which will simplify their treatment regime. We are delighted to partner with Accord, whose commercial expertise and extensive reach in Europe will advance the commercial roll-out of Jylamvo. Our partnership has begun apace with Jylamvo already launched in an additional two countries and promises to be driving force for the growth of our brand reputation in Europe as momentum continues to build.”
James Burt, Executive Vice President, Accord Healthcare Europe added:
“Our track record of marketing over 700 products globally allows us to provide extensive commercial support for Therakind’s lead product. We are committed to bringing new complex, value-added products to improve the lives of the patients within our expansive portfolio and we look forward to a mutually beneficial, successful partnership with Therakind.”
Enquiries:
Therakind Limited
Susan Conroy, Chief Executive Officer
Sam Race, Finance Director
Tel: +44 (0)208 346 6035
Email: admin@therakind.com
